Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and environmental factors, characterized by increased plasma glucose levels, mainly due to insufficient insulin secretion or dysfunction in the body (insulin resistance). Diabetes can be categorized into three primary forms - type 1, type 2, and gestational diabetes - each with distinct underlying causes. With the prevalence of diabetes increasing at an alarming rate, there is a critical need for innovative research solutions to better understand and combat this epidemic. The use of mouse models enables the study of diabetes in a way that closely mirrors the disease in humans, helping to explore disease mechanisms, find biomarkers, and evaluate potential treatments. Ace Therapeutics provides diverse diabetic mouse models targeting type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM). The T1DM mouse models allow resea

Glaucoma is a group of eye diseases characterized by damage to the optic nerve, usually due to high intraocular pressure (IOP). It is often referred to as the "silent thief of sight" because it can cause irreversible vision loss without any symptoms until it's too late. Causes of glaucoma Glaucoma is mainly caused by the increase in intraocular pressure (eye pressure). The anterior chamber located in front of the eye is filled with clear secretion (aqueous humor) that constantly flows in and out through the anterior chamber angle. If the flow of aqueous humor is blocked and cannot be drained, it will lead to an increase in eye pressure, causing compression of the optic nerve, poor blood circulation, and damage to the optic nerve. People with high myopia and long-term use of corticosteroid medicines, especially eye drops, or a history of eye trauma, are more likely to develop glaucoma. In addition, systemic diseases such as migraines, Raynaud's phenomenon, low blood pr

The innovative lead optimization is designed to help pharmaceutical companies develop effective drugs with high efficacy and less toxicity in response to the pressing need for new, effective treatments for diabetes. Diabetes is a complex metabolic disorder that demands tremendous research and innovation. The dedicated lead optimization program takes a novel approach, focusing on making marked improvements in diabetes drug discovery and development. Scientists remain committed to this vital area of human health and hope to contribute significantly to eradicating this widespread disease. Together with computational and medicinal chemists as well as advanced technologies, some CRO companies can provide customized lead optimization services to meet the specific needs of researchers in lead optimization. From stem cell optimization and gene therapy optimization to small molecule drug and antibody therapy optimization, these CROs utilize advanced techniques to support therapeutic devel